Company intelligence / Profile preview

Mission BioCapital

San Francisco, California, United Statesmissionbiocapital.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Mission BioCapital does not develop drugs directly but has enabled over 400 startups through its incubator network. Portfolio companies have brought 173 drug programs to clinic and 135 products to market. The Platinum Program has funded 16 early-stage life sciences startups with $7.5 million in pre-seed funding since 2022.

Industry: Investors

Partnerships

Eli Lilly and Company ("Lilly")Ono Venture Investment ("OVI")Alloy TherapeuticsHitGen

Beyond the preview

Go deeper on Mission BioCapital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mission BioCapital.

Explore the full profile